高级检索
当前位置: 首页 > 详情页

Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by survivin is at least partially p53-dependent: evidence for survivin acting as a transcription factor or co-factor.

文献详情

资源类型:
Pubmed体系:
机构: [a]Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA [b]Pre-Doctoral Chinese Fellowship Student, Second West China Hospital, Sichuan University, Sichuan, China
出处:
ISSN:

关键词: Survivin p21WAF1/CIP1 p21 promoter activity p53 Cancer cells

摘要:
Growing evidence suggests a role for the antiapoptotic protein survivin in promotion of cancer cell G1/S transition and proliferation. However, the underlying mechanism is unclear. Further, although upregulation of p21(WAF1/CIP1) by p53 plays an important role in p53-mediated cell G1 arrests in response to various distresses, it is unknown whether survivin plays a role in the regulation of p21(WAF1/CIP1) expression. Here, we report that exogenous expression of survivin in p53-wild type MCF-7 breast cancer cells inhibits the expression of p21(WAF1/CIP1) protein, mRNA and promoter activity, while the survivin C84A mutant and antisense failed to do so. Cotransfection experiments in the p53 mutant H1650 lung cancer cell line showed that survivin neutralizes p53-induced p21(WAF1/CIP1) expression and promoter activity. Importantly, genetically silencing of endogenous survivin using lentiviral survivin shRNA also enhances endogenous p21 in p53 wild type cancer cells, suggesting the physiological relevance of the fining. We further demonstrated that both p53 and survivin interacts on the two p53-binding sites in the p21(WAF1/CIP1) promoter (-2313 to -2212; -1452 to -1310), and survivin physically interacts with p53 in cancer cells. Together, we propose that survivin may act as a transcription factor or cofactor to interact with p53 on the p21(WAF1/CIP1) promoter leading to the inhibition of p21(WAF1/CIP1) expression at least in part by neutralizing p53-mediated transcriptional activation of the p21 gene. Copyright © 2012 Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 3 区 生物
小类 | 4 区 生化与分子生物学 4 区 生物物理
最新[2023]版:
大类 | 3 区 生物学
小类 | 3 区 生物物理 4 区 生化与分子生物学
第一作者:
第一作者机构: [a]Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA [b]Pre-Doctoral Chinese Fellowship Student, Second West China Hospital, Sichuan University, Sichuan, China
共同第一作者:
通讯作者:
通讯机构: [a]Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA [*1]Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43382 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号